Milnacipran and
duloxetine,
serotonin/noradrenalin reuptake inhibitors, and
pregabalin, a alpha(2)-delta(1) Ca(2+) channel blocker, are efficacious against
fibromyalgia, a condition characterized by diffuse
chronic pain and associated with stress. We compared these compounds (i.p. route), in rat models of acute/inflammatory
pain (2.5% intraplantar
formalin) and stress-induced ultrasonic vocalization (USV: 22kHz calls following presentation of a conditioned stimulus previously associated with foot-shocks). In the
formalin test,
milnacipran dose-dependently attenuated paw elevation and licking (minimal effective dose, MED: 2.5mg/kg for licking/late phase).
Duloxetine was slightly more potent (MED=0.63).
Pregabalin also reduced paw licking/late phase (MED=0.63), but was inactive up to 160mg/kg for paw elevation (both phases) and paw licking (early phase).
Milnacipran dose-dependently reduced USV (MED=10, near total inhibition at 20mg/kg);
duloxetine was less potent (MED=20).
Pregabalin (2.5-80mg/kg) was only significantly active at 40mg/kg.
Milnacipran,
duloxetine and
pregabalin possess
analgesic activity in the
formalin test on paw licking/late phase (corresponding to inflammatory
pain with a central sensitization component). In the stress-induced USV model,
milnacipran was the most potent and efficacious compound. To summarize, reduction of
formalin-induced paw licking/late phase might constitute a useful
indicator of potential activity against inflammatory/centrally sensitized
pain, as might be expressed in
fibromyalgia.